Forma Therapeutics Holdings (FMTX) Misses Q2 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. CVI
10. HNGE

Go back to Forma Therapeutics Holdings (FMTX) Misses Q2 EPS by 11c

Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 5, 2022 7:00 AM EDT

Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises

Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia

Highlighted progress across portfolio at inaugural Research and Development (R&D) Day

Appointed new members of Executive Team to prepare for growth in late-stage clinical development and... More